Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.
Insider & Institutional Ownership
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Monte Rosa Therapeutics and VistaGen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Monte Rosa Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
Monte Rosa Therapeutics presently has a consensus target price of $28.50, indicating a potential upside of 99.05%. VistaGen Therapeutics has a consensus target price of $0.95, indicating a potential upside of 295.83%. Given VistaGen Therapeutics’ higher possible upside, analysts plainly believe VistaGen Therapeutics is more favorable than Monte Rosa Therapeutics.
Volatility & Risk
Monte Rosa Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500.
Earnings and Valuation
This table compares Monte Rosa Therapeutics and VistaGen Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Monte Rosa Therapeutics | $123.67 million | 9.88 | -$38.63 million | ($1.76) | -8.14 |
| VistaGen Therapeutics | $1.27 million | 8.39 | -$69.68 million | ($1.66) | -0.14 |
Monte Rosa Therapeutics has higher revenue and earnings than VistaGen Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Monte Rosa Therapeutics beats VistaGen Therapeutics on 12 of the 15 factors compared between the two stocks.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
